A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD).

  • Wise, Claire (Primary Chief Investigator (PCI))
  • Mastwyk, Maree (Project Manager)
  • Thompson, Katherine (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date18/12/1819/05/20